Renascience Inc.
Notice Regarding Designation as a Rare Disease Drug for Skin Vascular Angiosarcoma
RS5614, a treatment for skin vascular angiosarcoma, has been designated as a rare disease drug by the Minister of Health, Labour and Welfare. Based on promising Phase II results in combination therapy and safety, discussions with PMDA for Phase III commencement continue. The designation offers pricing marketability enhancements and potential post-approval reexamination period extensions. No changes to the full-year forecast for the fiscal year ending March 2027.
Key Figures
- Efficacy rate: 13.3%
- Disease control rate: 86.7%
- Median progression-free survival: 4.0 months
- Median overall survival: 20.8 months
AI要約
IR News Highlights
Today, Renascience Inc. announces that RS5614, our skin vascular angiosarcoma treatment, has been designated as a rare disease drug by the Minister of Health, Labour and Welfare. Phase II results show an objective response rate of 13.3%, disease control rate of 86.7%, median progression-free survival of 4.0 months, and median overall survival of 20.8 months, indicating strong potential. Safety is favorable, and the final trial report has been confirmed as the Clinical Trial Summary Report. Discussions with PMDA for Phase III progression are ongoing. The pricing marketability premium and other incentives are expected to extend the exclusive period for the business. There is no change to the full-year forecast for the fiscal year ending March 2027.
Outlook and Impact
The designation as a rare disease drug is expected to bring benefits such as pricing marketability and extended reexamination periods, aiding post-approval business development and potential grants. In addition to continuing discussions with PMDA for Phase III, the fiscal year ending March 2027 forecast is not immediately affected, but any developments requiring disclosure will be announced in a timely manner.
Renascience Inc.
Company overview · Stock price · Financial data · All IR
